Our top pick for
Beyond Air, Inc is a medical devices business based in the US. Beyond Air shares (XAIR) are listed on the NASDAQ and all prices are listed in US Dollars. Beyond Air employs 23 staff and has a trailing 12-month revenue of around 0.00.
|52-week range||$4.65 - $8.90|
|50-day moving average||$5.65|
|200-day moving average||$5.74|
|Wall St. target price||$13.25|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-1.49|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|Gross profit TTM||$1.4 million|
|Return on assets TTM||-67.46%|
|Return on equity TTM||-156.79%|
|Market capitalisation||$109 million|
TTM: trailing 12 months
There are currently 2.3 million Beyond Air shares held short by investors – that's known as Beyond Air's "short interest". This figure is 19.9% up from 1.9 million last month.
There are a few different ways that this level of interest in shorting Beyond Air shares can be evaluated.
Beyond Air's "short interest ratio" (SIR) is the quantity of Beyond Air shares currently shorted divided by the average quantity of Beyond Air shares traded daily (recently around 367289.21095008). Beyond Air's SIR currently stands at 6.21. In other words for every 100,000 Beyond Air shares traded daily on the market, roughly 6210 shares are currently held short.
However Beyond Air's short interest can also be evaluated against the total number of Beyond Air shares, or, against the total number of tradable Beyond Air shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Beyond Air's short interest could be expressed as 0.11% of the outstanding shares (for every 100,000 Beyond Air shares in existence, roughly 110 shares are currently held short) or 0.1208% of the tradable shares (for every 100,000 tradable Beyond Air shares, roughly 121 shares are currently held short).
A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Beyond Air.
Find out more about how you can short Beyond Air stock.
We're not expecting Beyond Air to pay a dividend over the next 12 months.
Over the last 12 months, Beyond Air's shares have ranged in value from as little as $4.651 up to $8.8999. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Beyond Air's is -0.6399. This would suggest that Beyond Air's shares have been inversely-correlated to the average (for this exchange) – so when the broader market trended up or down, Beyond Air has bucked the trend.
Beyond Air, Inc. , a clinical-stage medical device and biopharmaceutical company, develops inhaled nitric oxide (NO) to treat respiratory infections, and gaseous NO to treat solid tumors. The company is developing LungFit system, a NO generator and delivery system, which is in clinical trials for the treatment of lung infections, persistent pulmonary hypertension of the newborn, severe acute respiratory syndrome coronavirus 2, bronchiolitis, and nontuberculous mycobacteria. The company was formerly known as AIT Therapeutics, Inc. and changed its name to Beyond Air, Inc. in June 2019. The company is based in Garden City, New York.
Everything we know about the TC Bancshares IPO, plus information on how to buy in.
Everything we know about the Soulgate IPO, plus information on how to buy in.
Everything we know about the Alzamend Neuro IPO, plus information on how to buy in.
Everything we know about the Singular Genomics Systems IPO, plus information on how to buy in.
Everything we know about the Golden Sun Education Group Limited IPO, plus information on how to buy in.
Everything we know about the Phillips Edison & Company IPO, plus information on how to buy in.
Everything we know about the FIGS IPO, plus information on how to buy in.
Everything we know about the DLocal Limited IPO, plus information on how to buy in.
Everything we know about the Torchy’s Tacos IPO, plus information on how to buy in.
Everything we know about the Dutch Bros Coffee IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.